Plus therapeutics reports respect-lm phase 1 trial data at the 2023 sno/asco cns cancer conference

Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases

PSTV Ratings Summary

PSTV Quant Ranking